Anand Patel Spends ₹13m Buying Lincoln Pharmaceuticals Shares

Potential Lincoln Pharmaceuticals Limited (NSE:LINCOLN) shareholders may wish to note that insider Anand Patel recently bought ₹13m worth of stock, paying ₹641 for each share. Although the purchase only increased their holding by 7.1%, it is still a solid purchase in our view.

View our latest analysis for Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Insider Transactions Over The Last Year

The Head of Sales & Marketing and Whole Time Director Ashish Patel made the biggest insider purchase in the last 12 months. That single transaction was for ₹30m worth of shares at a price of ₹488 each. We do like to see buying, but this purchase was made at well below the current price of ₹694. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

Lincoln Pharmaceuticals insiders may have bought shares in the last year, but they didn't sell any. The average buy price was around ₹423. It is certainly positive to see that insiders have invested their own money in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Lincoln Pharmaceuticals is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Does Lincoln Pharmaceuticals Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. It's great to see that Lincoln Pharmaceuticals insiders own 53% of the company, worth about ₹7.4b. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

What Might The Insider Transactions At Lincoln Pharmaceuticals Tell Us?

The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Lincoln Pharmaceuticals. Looks promising! I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph.

But note: Lincoln Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.